Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


The Impact of Clinical Trials in Tennessee


 
Sen. Mark Green, MD, discusses the importance of local clinical trials and biopharmaceutical research in Tennessee. Pictured (L-R) James and Josi Felts, Dr. Paul Newhouse, Dr. Jeffrey Conn, and Sen. Mark Green.

On Jan. 23, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 945 active clinical trials in the Tennessee. Additionally, the report said the life science industry supports 52,000 jobs and contributes $11.7 billion to the state's economy.

"Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in Tennessee," was released at an event held at the Cordell Hull Building, which featured a panel discussion by Vanderbilt University Medical Center biotech researchers, Tennessee State Senator Mark Green, MD, (R-22), and a local Alzheimer's disease patient and clinical trial participant.

"Clinical trials offer patients novel medical treatments while also allowing biopharma research organizations to innovate and grow," said Green, founder of Align MD. "Across the state - and particularly here in Nashville - the healthcare industry has had a profound impact on our economy."

In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations. In Tennessee, active trials are studying treatment options for more than 20 disease sites or types, with cancer trials leading the way by a large margin. Of the 945 open clinical trials involving the biopharmaceutical research industry, Vanderbilt is collaborating on more than 245 of them. In addition, the report cites Meharry Medical College, Sarah Cannon, Clinical Research Associates, Tennessee Clinical Research Center, Tennessee Oncology, Tennessee Retina, and all of the city's major hospitals and health systems as active participants in Nashville.

"Many top universities call Tennessee home and are centers of innovation," said Jeffrey Conn, PhD, director of the Vanderbilt Center for Neuroscience Drug Discovery. "Maintaining strong partnerships between medical universities and life science companies allows us to foster developments right here in Tennessee that can then help save lives far beyond our state lines."

On average, it takes approximately a decade for new medicines to go through the FDA approval process, and only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted more than 6,100 clinical trials in Tennessee.

The complete report is available online at NashvilleMedicalNews.com

WEB:

Research in Your Backyard Report

 
Share:

Related Articles:


Recent Articles

Study Finds Certain Genetic Test Not Useful in Predicting Heart Disease Risk

A Polygenic Risk Score -- a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients -- has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.

Read More

Tennessee Infants Exposed to Hep C at Birth Often Not Tested for Virus

Most Tennessee infants exposed to hepatitis C at birth are not later tested to see if they acquired the virus, according to a study by researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Center for Child Health Policy.

Read More

THA, TMA, TNA Outline Legislative Priorities

With the Tennessee General Assembly back in full swing, the state's major healthcare associations outline 2020 priorities.

Read More

Cardiac Innovation in Nashville

From transplants to trials, Nashville hospitals are leading the way in cardiac care.

Read More

A Modern Love Story: Where Technology, Healthcare & Construction Go Hand-in-Hand

Technology has changed every aspect of our lives. In fact, I had a healthy laugh a few weeks ago when I showed my children an old rotary phone and, get this, they did not know what it was.

Read More

Reeves/Smith Bill to Prevent Next Generation of Nicotine Addiction Garners Broad Industry Support

In late January, a group of more than 25 organizations from across Tennessee announced their support for legislation that seeks to prevent the next generation of nicotine addicts in the state.

Read More

Physician Spotlight: A Heart for Healing

TriStar Summit cardiologist Kristen Kerr is passionate about education, improving outcomes in women's heart health.

Read More

Heart Monitor

Read More

Ifetroban for Treating DMD-Associated Cardiomyopathy

Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.

Read More

Endocrine Society Celebrates Progress from Bench to Bedside

Endocrine Society Chief Professional & Clinical Affairs Officer Robert Lash, MD, discusses the field, annual meeting, road shows and more.

Read More

Email Print
 
 

 

 


Tags:
Biopharmaceutical Research, Clinical Trials, Jeffrey Conn, Life Sciences, Mark Green, Pharmaceutical Research and Manufacturers of America, Pharmaceuticals, PhRMA, Research in Your Backyard, Vanderbilt
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: